Abstract:BACKGROUND: Achromobacter xylosoxidans is increasingly cultured in sputum from cystic fibrosis (CF) patients; nevertheless, there are few published data on the clinical impact of this infection or chronic colonisation.METHODS: Relying on DNA fingerprinting techniques we studied the prevalence of A. xylosoxidans in our CF population. In a retrospective case control study the clinical status of patients with at least 3 sputum cultures positive for A. xylosoxidans over at least 9 months, at the moment of the first positive culture and during the period of colonisation were compared to age (+/-1 year), gender and to Pseudomonas aeruginosa colonisation controlled CF patients who had never A. xylosoxidans positive sputum cultures.RESULTS: The prevalence of patients with at least one positive A. xylosoxidans culture was 17.9%. 5.3% of the patients fulfilled the criteria of our definition of colonisation. Colonised patients had a median age of 20 years (range 11-27 years) and a mean colonisation period of 1.5 (+/-0.9) years. At the moment of the first positive culture we found significantly lower Bhalla scores on HRCT scans of the lungs (11+/-3 versus 16+/-3, p<0.002), lower Brasfield chest X-ray scores (14+/-3 versus 18+/-3, p<0.019), lower FVC values (70%+/-22 versus 94%+/-12, p<0.017) and lower FEV(1) values (55%+/-32 versus 78%+/-23, p=0.123), although the latter did not reach significance. There was no significant difference in body mass index (BMI) (18.7+/-3 kg/m2 versus 19.6+/-3 kg/m2, p=0.8). Over the study period A. xylosoxidans-colonised patients did have more need for intravenous antibiotic treatment courses (19 versus 5, p<0.001); nevertheless, there was no significant difference in lung function decline over the study period (FVC: -6.25+/-12.34% versus -5.62+/-8.30%, p 0.77, FEV1: -5.62+/-8.30% versus -1.87+/-11.58%, p<0.47).CONCLUSIONS: The prevalence of A. xylosoxidans infection or colonisation is probably underestimated. Colonised patients are mostly older, with more pronounced lung damage and lower lung function values. Although there was more need for intravenous antibiotic treatment courses, no faster decline in lung function was observed in A. xylosoxidans positive patients.

Co-colonisation with Aspergillus fumigatus and Pseudomonas aeruginosa is associated with poorer health in cystic fibrosis patients: an Irish registry analysis

Long-Term Outcomes of Allergic Bronchopulmonary Aspergillosis and Aspergillus Colonization in Children and Adolescents with Cystic Fibrosis

Risk factors for respiratory Aspergillus fumigatus in German Cystic Fibrosis patients and impact on lung function

An invisible threat? Aspergillus positive cultures and co-infecting bacteria in airway samples

Persistent Aspergillus fumigatus infection in cystic fibrosis: impact on lung function and role of treatment of asymptomatic colonization—a registry-based case–control study

Factoring in the Complexity of the Cystic Fibrosis Lung to Understand Aspergillus fumigatus and Pseudomonas aeruginosa Interactions

Achromobacter xylosoxidans in cystic fibrosis: Prevalence and clinical relevance

Assessment of Aspergillus sensitization or persistent carriage as a factor in lung function impairment in cystic fibrosis patients

P174 High Aerosol Production of Potentially Infectious Cough Aerosols in People with Cystic Fibrosis During Coughing

Molecular epidemiology of Aspergillus species and other moulds in respiratory samples from Argentinean patients with cystic fibrosis.

The relationship of clinical and inflammatory markers to outcome in stable patients with cystic fibrosis

The Real-World Effectiveness of Antifungals in People with Cystic Fibrosis and Aspergillus-Positive Cultures

The Impact of Pseudomonas aeruginosa Infection in Adult Cystic Fibrosis Patients—A Single Polish Centre Study

Anti-Fungal (Aspergillus fumigatus) Activity of Pseudomonas aeruginosa in Cystic Fibrosis Synthetic Sputum

Molecular Mechanisms of Staphylococcus and Pseudomonas Interactions in Cystic Fibrosis

Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients

Respiratory Aspergillus Colonization Was Associated With Relapse of Acute Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Analysis of Data From A Retrospective Cohort Study

Airway commensal bacteria in cystic fibrosis inhibit the growth of P. aeruginosa via a released metabolite

Adaptive Interactions of Achromobacter spp. with Pseudomonas aeruginosa in Cystic Fibrosis Chronic Lung Co-Infection

Impact of CFTR Modulation on Pseudomonas aeruginosa Infection in People With Cystic Fibrosis

The airway microbiome in cystic fibrosis and implications for treatment